Swiss cannabis pilot projects — 2026 overview

Seven Swiss cities — Zurich (Züri Can, 2,100 participants), Bern (SCRIPT, ~1,000), Basel (Weed Care, ~370), Lausanne (Cann-L, launch 2025), Geneva, Lucerne and Winterthur — have been trialling regulated THC cannabis sales since 2022 under Art. 8a of the Narcotics Act. Goal: produce scientifically sound data on how a regulated market affects consumption, black-market share and public health. Interim reports (Weed Care 2024, Züri Can 2025) consistently show: no increase in consumption, 78 % of purchases shifted away from the black market, dramatic reduction in synthetic adulterants, -40 % unit cost at controlled quality. This hub bundles the site map, eligibility (18+, residency 3–6 months, existing consumer, medical screening), prices and products per project, current study figures and the political roadmap through 2031 — including a comparison with Germany's KCanG model and the Maltese CSC framework.

We compare the SCRIPT (Basel), Züri Can (Zurich), WeedCare (Basel-Land), Cann-L (Lausanne) and Bern pilot studies by participants, price, THC content, product rotation and accompanying research. Included: inclusion/exclusion criteria plus 2026 waiting-list status.